239 related articles for article (PubMed ID: 11081189)
1. Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients.
Marzullo P; Ferone D; Di Somma C; Pivonello R; Filippella M; Lombardi G; Colao A
Pituitary; 1999; 1(2):115-20. PubMed ID: 11081189
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly.
Colao A; Marzullo P; Ferone D; Marinò V; Pivonello R; Di Somma C; Di Sarno A; Giaccio A; Lombardi G
J Endocrinol Invest; 1999 Jan; 22(1):40-7. PubMed ID: 10090136
[TBL] [Abstract][Full Text] [Related]
3. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
5. Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg).
Baldelli R; Colao A; Razzore P; Jaffrain-Rea ML; Marzullo P; Ciccarelli E; Ferretti E; Ferone D; Gaia D; Camanni F; Lombardi G; Tamburrano G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4099-103. PubMed ID: 11095439
[TBL] [Abstract][Full Text] [Related]
6. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
Minniti G; Jaffrain-Rea ML; Baldelli R; Ferretti E; Caracciolo B; Bultrini A; Gulino A; Tamburrano G
Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
8. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
9. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
10. A 12-month randomized crossover study on the effects of lanreotide Autogel and octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly.
Andries M; Glintborg D; Kvistborg A; Hagen C; Andersen M
Clin Endocrinol (Oxf); 2008 Mar; 68(3):473-80. PubMed ID: 17941902
[TBL] [Abstract][Full Text] [Related]
11. A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly.
Cozzi R; Dallabonzana D; Attanasio R; Barausse M; Oppizzi G
Eur J Endocrinol; 1999 Sep; 141(3):267-71. PubMed ID: 10474124
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly.
Ambrosio MR; Franceschetti P; Bondanelli M; Doga M; Maffei P; Baldelli R; Tamburrano G; Sicolo N; Giustina A; degli Uberti EC
Metabolism; 2002 Mar; 51(3):387-93. PubMed ID: 11887179
[TBL] [Abstract][Full Text] [Related]
13. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
14. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
15. [Estimation of efficacy of the octreotide LAR administration in the patients with somatotropinoma].
Waśko R; Bolko P; Kostrzewski J; Horst-Sikorska W; Liebert W; Sowiński J
Pol Arch Med Wewn; 2001 Aug; 106(2):693-8. PubMed ID: 11926144
[TBL] [Abstract][Full Text] [Related]
16. Role of the addition of cabergoline to the management of acromegalic patients resistant to longterm treatment with octreotide LAR.
Vilar L; Azevedo MF; Naves LA; Casulari LA; Albuquerque JL; Montenegro RM; Montenegro RM; Figueiredo P; Nascimento GC; Faria MS
Pituitary; 2011 Jun; 14(2):148-56. PubMed ID: 21104199
[TBL] [Abstract][Full Text] [Related]
17. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
Giusti M; Gussoni G; Cuttica CM; Giordano G
J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
[TBL] [Abstract][Full Text] [Related]
19. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly.
Tutuncu Y; Berker D; Isik S; Ozuguz U; Akbaba G; Kucukler FK; Aydin Y; Guler S
Pituitary; 2012 Sep; 15(3):398-404. PubMed ID: 21863263
[TBL] [Abstract][Full Text] [Related]
20. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
